Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis
Richard A Hansen1, Gerald Gartlehner2, Aaron P Webb1, Laura C Morgan3, Charity G Moore4, Daniel E Jonas31School of Pharmacy, 3Cecil G Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, NC, USA; 2Department for Evidence-based Medicine and Clinical Epidemiology, Danu...
Guardado en:
Autores principales: | Richard A Hansen, Gerald Gartlehner, Aaron P Webb, Laura C Morgan, Charity G Moore, Daniel E Jonas |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d5c15d92899e49d28e97a25f7619b761 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinical efficacy and safety of donepezil in the treatment of Alzheimer’s disease in Chinese patients
por: Zhang N, et al.
Publicado: (2018) -
Galantamine versus donepezil in Chinese patients with Alzheimer’s disease: results from a randomized, double-blind study
por: Zhang Z, et al.
Publicado: (2012) -
Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer’s disease receiving donepezil
por: Kano O, et al.
Publicado: (2013) -
Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
por: Ben Seltzer
Publicado: (2009) -
Two cases of Alzheimer's disease showing deterioration of behavioral and psychological symptoms of dementia induced by switching from rivastigmine to donepezil
por: Kimura T, et al.
Publicado: (2012)